Nektar Therapeutics (NKTR) Set to Announce Earnings on Thursday

Nektar Therapeutics (NASDAQ:NKTR) is scheduled to be posting its quarterly earnings results after the market closes on Thursday, November 7th. Analysts expect Nektar Therapeutics to post earnings of ($0.23) per share for the quarter. Investors that wish to listen to the company’s conference call can do so using this link.

Nektar Therapeutics (NASDAQ:NKTR) last issued its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.04). Nektar Therapeutics had a negative return on equity of 133.64% and a negative net margin of 190.09%. The company had revenue of $23.49 million for the quarter, compared to the consensus estimate of $17.24 million. During the same period in the prior year, the firm posted ($0.27) earnings per share. On average, analysts expect Nektar Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Nektar Therapeutics Stock Up 4.1 %

NASDAQ:NKTR traded up $0.06 during trading hours on Tuesday, hitting $1.39. 1,686,754 shares of the company traded hands, compared to its average volume of 1,749,704. The company has a market cap of $254.95 million, a PE ratio of -1.56 and a beta of 0.61. The firm’s 50-day simple moving average is $1.28 and its 200-day simple moving average is $1.34. Nektar Therapeutics has a one year low of $0.41 and a one year high of $1.93.

Wall Street Analysts Forecast Growth

NKTR has been the topic of several analyst reports. Piper Sandler began coverage on shares of Nektar Therapeutics in a report on Monday. They set an “overweight” rating and a $7.00 price target on the stock. BTIG Research restated a “buy” rating and issued a $4.00 target price on shares of Nektar Therapeutics in a research note on Monday, September 30th. One analyst has rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the company. According to MarketBeat.com, Nektar Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $3.50.

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.